Treatment of cancer

Fecha de publicación: 11/02/2016
Fuente: WIPO "miel"
Provided are methods relating to compositions that include a CDP- topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.